- Home
- CIGI vs JAZZ Comparison
CIGI vs JAZZ Comparison
Compare CIGI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGI
- JAZZ
- Stock Information
- Founded
- CIGI 1972
- JAZZ 2003
- Country
- CIGI Canada
- JAZZ Ireland
- Employees
- CIGI N/A
- JAZZ N/A
- Industry
- CIGI
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CIGI
- JAZZ Health Care
- Exchange
- CIGI Nasdaq
- JAZZ Nasdaq
- Market Cap
- CIGI 6.8B
- JAZZ 6.7B
- IPO Year
- CIGI N/A
- JAZZ 2007
- Fundamental
- Price
- CIGI $142.37
- JAZZ $118.23
- Analyst Decision
- CIGI Buy
- JAZZ Strong Buy
- Analyst Count
- CIGI 7
- JAZZ 12
- Target Price
- CIGI $160.33
- JAZZ $183.00
- AVG Volume (30 Days)
- CIGI 126.7K
- JAZZ 636.6K
- Earning Date
- CIGI 07-31-2025
- JAZZ 08-04-2025
- Dividend Yield
- CIGI 0.21%
- JAZZ N/A
- EPS Growth
- CIGI 38.82
- JAZZ 49.21
- EPS
- CIGI 2.86
- JAZZ 7.51
- Revenue
- CIGI $4,961,214,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- CIGI $13.69
- JAZZ $6.00
- Revenue Next Year
- CIGI $6.68
- JAZZ $4.85
- P/E Ratio
- CIGI $49.70
- JAZZ $15.74
- Revenue Growth
- CIGI 13.50
- JAZZ 5.76
- 52 Week Low
- CIGI $100.86
- JAZZ $95.49
- 52 Week High
- CIGI $156.96
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- CIGI 73.15
- JAZZ 65.45
- Support Level
- CIGI $137.64
- JAZZ $115.92
- Resistance Level
- CIGI $142.50
- JAZZ $119.48
- Average True Range (ATR)
- CIGI 3.34
- JAZZ 2.88
- MACD
- CIGI 0.51
- JAZZ 0.71
- Stochastic Oscillator
- CIGI 96.84
- JAZZ 89.25
About CIGI Colliers International Group Inc. Subordinate Voting Shares
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are; Real Estate Services, Engineering, Investment Management, and Corporate. Maximum revenue for the company is generated from its Real Estate Services segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, property sales brokerage, and lease brokerage services, among others. Geographically, the company generates maximum revenue from the United States and the rest from Canada, Australia, the United Kingdom, Poland, China, India, and other regions.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.